Literature DB >> 18437576

The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis.

Lilian Sewing1, Florian Steinberg, Harald Schmidt, Rüdiger Göke.   

Abstract

Besides its preventive action on bone resorption the third generation bisphosphonate zoledronic acid (ZOL) has been shown to display potent inhibitory action on the formation of bone metastases of various human cancers. Recent research also indicates an antitumoral effect on primary tumors and visceral metastases. Here we investigate for the first time the effect of ZOL on the human colon carcinoma cell line HCT-116. ZOL strongly inhibited the proliferation and soft agar colony formation of HCT-116 cells and caused a G1 cell cycle arrest in a population of ZOL treated cells. This cell cycle arrest was accompanied by an induction of apoptosis via a caspase dependent mechanism. Activation of Caspases 3, 7, 8 and 9, cleavage of PARP as well as the release of cytochrome C into the cytosol were detected in HCT-116 cells treated with low micromolar concentrations of ZOL. The induction of the mitochondrial pathway of apoptosis was accompanied by a translocation of Bax into the mitochondria, Bid activation and a decrease of overall Bcl-2 expression. We also detected a cytosolic increase of apoptosis inducing factor (AIF), a trigger of caspase-independent apoptosis. Taken together, our data indicate a potent antitumoral and apoptosis inducing effect of ZOL on HCT-116 colon carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437576     DOI: 10.1007/s10495-008-0211-z

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  20 in total

1.  Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.

Authors:  K Sun; J M Liu; H X Sun; N Lu; G Ning
Journal:  Osteoporos Int       Date:  2012-10-06       Impact factor: 4.507

2.  Zoledronate can promote apoptosis and inhibit the proliferation of colorectal cancer cells.

Authors:  Xiang Gao; Bo Jiang; Shitao Zou; Ting Zhang; Xiaowei Qi; Linfang Jin; Xiaosong Ge; Shou-Ching Tang; Dong Hua; Weichang Chen
Journal:  Tumour Biol       Date:  2015-02-15

3.  Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.

Authors:  M Pazianas; B Abrahamsen; P A Eiken; R Eastell; R Graham G Russell
Journal:  Osteoporos Int       Date:  2012-03-06       Impact factor: 4.507

4.  Exposure to oral bisphosphonates and risk of gastrointestinal cancer.

Authors:  D Choi; S Choi; J Chang; S M Park
Journal:  Osteoporos Int       Date:  2020-02-07       Impact factor: 4.507

Review 5.  Primary prevention of colorectal cancer: myth or reality?

Authors:  Marcela Crosara Teixeira; Maria Ignez Braghiroli; Jorge Sabbaga; Paulo M Hoff
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 6.  Exposure to bisphosphonates and risk of colorectal cancer.

Authors:  Jingjing Ma; Sheng Gao; Xiaojian Ni; Fei Chen; Xiaofeng Liu; Hui Xie; Hong Yin; Cheng Lu
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 7.  Oral bisphosphonates and colon cancer: an update.

Authors:  Pia Eiken; Peter Vestergaard
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

8.  Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.

Authors:  Stefanos Bonovas; Georgios Nikolopoulos; Pantelis Bagos
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

9.  Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells.

Authors:  Laura M Mitrofan; Ferran B Castells; Jukka Pelkonen; Jukka Mönkkönen
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

10.  Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.

Authors:  Cigir Biray Avci; Cansu Caliskan Kurt; Burcu Erbaykent Tepedelen; Ozgun Ozalp; Bakiye Goker; Zeynep Mutlu; Yavuz Dodurga; Levent Elmas; Cumhur Gunduz
Journal:  Tumour Biol       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.